| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | <1 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Evaluating a Lifestyle Intervention to Prevent Recurrence of Diabetic Foot Ulcers | N/A | University of Southern California | <1 mi |
| Smart Boot Use to Measure Offloading Adherence | Phase 2 | University of Southern California | <1 mi |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | Bayer | <1 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | <1 mi |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus | Phase 1 | Eli Lilly and Company | <1 mi |
| A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers | N/A | Integra LifeSciences Corporation | <1 mi |
| Continuous Glucose Monitoring in Prediabetes With Health Education Videos | N/A | David S Black, PhD | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | <1 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | <1 mi |
| Type 2 Continuous Glucose Monitoring Academy | N/A | Children's Hospital Los Angeles | <1 mi |
| Device Use Reimagined Through Education And Mentorship | N/A | University of California, San Francisco | <1 mi |
| Implementation of Team Clinic for Type 2 Diabetes (TCT2) | N/A | Children's Hospital Los Angeles | <1 mi |
| DFC 004 Biomarkers for Active Diabetic Foot Ulcers | — | University of Michigan | <1 mi |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Phase 2 | Walden Biosciences | <1 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | <1 mi |
| New T-UP: Engaging Vulnerable Students in Diabetes Prevention | N/A | University of California, Los Angeles | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| CGM Academy for Youth With Type 1 Diabetes | N/A | Children's Hospital Los Angeles | <1 mi |
| This Study is to Evaluate Whether Receiving Education and Glucose Monitoring With the CGM Device Will Improve Patient-reported Outcomes by Improving Patient's Satisfaction and Quality of Life (QOL) With Glucose Monitoring Device | — | Cedars-Sinai Medical Center | <1 mi |
| Continuous Glucose Monitoring (CGM) in Prediabetes With Health Education Videos: Cohort 3 | N/A | David S Black, PhD | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics | — | Milton S. Hershey Medical Center | <1 mi |
| DETERMINE: Detemir vs NPH | Phase 2 | University of California, Los Angeles | <1 mi |
| Adapting Lifestyle Offloading for DFUs | N/A | University of Southern California | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms | — | Milton S. Hershey Medical Center | <1 mi |
| Designing Team Clinic for Youth With Type 2 Diabetes | — | Children's Hospital Los Angeles | <1 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers | N/A | Tides Medical | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center | N/A | Cedars-Sinai Medical Center | <1 mi |
| Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial | N/A | University of California, Los Angeles | <1 mi |
| Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) | — | M.D. Anderson Cancer Center | <1 mi |
| A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. | N/A | Molnlycke Health Care AB | <1 mi |
| Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D) | N/A | Children's Hospital Los Angeles | <1 mi |
| Type 2 Diabetes and Blood Brain Barrier Improvement | Early 1 | University of California, Los Angeles | <1 mi |
| Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children | N/A | University of Southern California | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | 5 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 5 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | 6 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | 6 mi |
| A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years | Phase 1 | AstraZeneca | 6 mi |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort | Phase 1 | AstraZeneca | 6 mi |
| Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | Phase 1 | Merck Sharp & Dohme LLC | 6 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | 9 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | 9 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 9 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 9 mi |
| Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions | Phase 1/2 | Thomas Advanced Medical LLC | 9 mi |
| A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Phase 2 | Vantage Biosciences Ltd | 9 mi |
| Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Phase 3 | Kailera | 10 mi |
| Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. | Phase 4 | Royal Biologics | 10 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | 11 mi |
| Starting Technology in At Risk Type 1 Diabetes Study | N/A | University of California, Los Angeles | 14 mi |
| Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Phase 4 | Matthew J. Budoff | 16 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | 16 mi |
| Denosumab for Type 1 Diabetes | Phase 1/2 | City of Hope Medical Center | 16 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | 16 mi |
| Circulating Biomarkers in the Development of Type 1 Diabetes | — | City of Hope Medical Center | 16 mi |
| Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes | Phase 1/2 | City of Hope Medical Center | 16 mi |
| Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | 17 mi |
| Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Phase 2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 18 mi |
| Different Doses of Naronapride Vs. Placebo in Gastroparesis | Phase 2 | Dr. Falk Pharma GmbH | 18 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | 19 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 19 mi |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | 20 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | 20 mi |
| Immediate Postpartum Glucose Tolerance Testing | — | MemorialCare Health System | 20 mi |
| A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | 20 mi |
| A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine | N/A | Southern California Institute for Research and Education | 20 mi |
| A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | Phase 1/2 | Metsera, a wholly owned subsidiary of Pfizer | 20 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | 21 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Phase 3 | Kailera | 21 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Phase 3 | Kailera | 21 mi |
| High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy | Phase 4 | Retina Consultants of Orange County | 22 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 25 mi |
| Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial | N/A | University of California, Irvine | 29 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | 29 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | 30 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | 30 mi |
| Conscious Pregnancy: Supporting Maternal Cardiometabolic Health With Mindfulness | N/A | University of California, Irvine | 30 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 30 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 30 mi |
| EDX110 Randomized Control Trial for Treatment of DFUs | N/A | ConvaTec Inc. | 30 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | 31 mi |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Phase 2 | Eli Lilly and Company | 32 mi |
| Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers | N/A | Axolotl Biologix | 35 mi |
| The iLet Experience Study | — | Beta Bionics, Inc. | 36 mi |
| HOPE Intervention for Fitness | N/A | University of California, Irvine | 36 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | 37 mi |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Ascletis Pharma (China) Co., Limited | 49 mi |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Eli Lilly and Company | 49 mi |